The global clinical trial materials manufacturing market is expanding with growing demand for efficient supply chains and customized solutions in clinical research. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clinical Trial Materials Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clinical Trial Materials Manufacturing Market, by Product Type
8.1.1. Investigational Medicinal Products (IMPs)
8.1.1.1. Market Revenue and Forecast
8.1.2. Placebos
8.1.2.1. Market Revenue and Forecast
8.1.3. Comparator Drugs
8.1.3.1. Market Revenue and Forecast
8.1.4. Ancillary Materials
8.1.4.1. Market Revenue and Forecast
9.1. Clinical Trial Materials Manufacturing Market, by Service Type
9.1.1. Manufacturing
9.1.1.1. Market Revenue and Forecast
9.1.2. Packaging
9.1.2.1. Market Revenue and Forecast
9.1.3. Labeling
9.1.3.1. Market Revenue and Forecast
9.1.4. Distribution
9.1.4.1. Market Revenue and Forecast
10.1. Clinical Trial Materials Manufacturing Market, by Clinical Trial Phase
10.1.1. Phase I
10.1.1.1. Market Revenue and Forecast
10.1.2. Phase II
10.1.2.1. Market Revenue and Forecast
10.1.3. Phase III
10.1.3.1. Market Revenue and Forecast
10.1.4. Phase IV
10.1.4.1. Market Revenue and Forecast
11.1. Clinical Trial Materials Manufacturing Market, by Therapeutic Area
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Forecast
11.1.3. Neurology
11.1.3.1. Market Revenue and Forecast
11.1.4. Infectious Diseases
11.1.4.1. Market Revenue and Forecast
11.1.5. Rare Diseases
11.1.5.1. Market Revenue and Forecast
11.1.6. Endocrinology
11.1.6.1. Market Revenue and Forecast
11.1.7. Immunology
11.1.7.1. Market Revenue and Forecast
11.1.8. Respiratory
11.1.8.1. Market Revenue and Forecast
11.1.9. Dermatology
11.1.9.1. Market Revenue and Forecast
11.1.10. Gastroenterology
11.1.10.1. Market Revenue and Forecast
12.1. Clinical Trial Materials Manufacturing Market, by End-User
12.1.1. Pharmaceutical Companies
12.1.1.1. Market Revenue and Forecast
12.1.2. Biotechnology Firms
12.1.2.1. Market Revenue and Forecast
12.1.3. Contract Research Organizations (CROs)
12.1.3.1. Market Revenue and Forecast
12.1.4. Academic Research Institutions
12.1.4.1. Market Revenue and Forecast
12.1.5. Government Research Bodies
12.1.5.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type
13.1.2. Market Revenue and Forecast, by Service Type
13.1.3. Market Revenue and Forecast, by Clinical Trial Phase
13.1.4. Market Revenue and Forecast, by Therapeutic Area
13.1.5. Market Revenue and Forecast, by End-User
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type
13.1.6.2. Market Revenue and Forecast, by Service Type
13.1.6.3. Market Revenue and Forecast, by Clinical Trial Phase
13.1.6.4. Market Revenue and Forecast, by Therapeutic Area
13.1.6.5. Market Revenue and Forecast, by End-User
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type
13.1.7.2. Market Revenue and Forecast, by Service Type
13.1.7.3. Market Revenue and Forecast, by Clinical Trial Phase
13.1.7.4. Market Revenue and Forecast, by Therapeutic Area
13.1.7.5. Market Revenue and Forecast, by End-User
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type
13.2.2. Market Revenue and Forecast, by Service Type
13.2.3. Market Revenue and Forecast, by Clinical Trial Phase
13.2.4. Market Revenue and Forecast, by Therapeutic Area
13.2.5. Market Revenue and Forecast, by End-User
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type
13.2.6.2. Market Revenue and Forecast, by Service Type
13.2.6.3. Market Revenue and Forecast, by Clinical Trial Phase
13.2.7. Market Revenue and Forecast, by Therapeutic Area
13.2.8. Market Revenue and Forecast, by End-User
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type
13.2.9.2. Market Revenue and Forecast, by Service Type
13.2.9.3. Market Revenue and Forecast, by Clinical Trial Phase
13.2.10. Market Revenue and Forecast, by Therapeutic Area
13.2.11. Market Revenue and Forecast, by End-User
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type
13.2.12.2. Market Revenue and Forecast, by Service Type
13.2.12.3. Market Revenue and Forecast, by Clinical Trial Phase
13.2.12.4. Market Revenue and Forecast, by Therapeutic Area
13.2.13. Market Revenue and Forecast, by End-User
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type
13.2.14.2. Market Revenue and Forecast, by Service Type
13.2.14.3. Market Revenue and Forecast, by Clinical Trial Phase
13.2.14.4. Market Revenue and Forecast, by Therapeutic Area
13.2.15. Market Revenue and Forecast, by End-User
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type
13.3.2. Market Revenue and Forecast, by Service Type
13.3.3. Market Revenue and Forecast, by Clinical Trial Phase
13.3.4. Market Revenue and Forecast, by Therapeutic Area
13.3.5. Market Revenue and Forecast, by End-User
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type
13.3.6.2. Market Revenue and Forecast, by Service Type
13.3.6.3. Market Revenue and Forecast, by Clinical Trial Phase
13.3.6.4. Market Revenue and Forecast, by Therapeutic Area
13.3.7. Market Revenue and Forecast, by End-User
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type
13.3.8.2. Market Revenue and Forecast, by Service Type
13.3.8.3. Market Revenue and Forecast, by Clinical Trial Phase
13.3.8.4. Market Revenue and Forecast, by Therapeutic Area
13.3.9. Market Revenue and Forecast, by End-User
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type
13.3.10.2. Market Revenue and Forecast, by Service Type
13.3.10.3. Market Revenue and Forecast, by Clinical Trial Phase
13.3.10.4. Market Revenue and Forecast, by Therapeutic Area
13.3.10.5. Market Revenue and Forecast, by End-User
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type
13.3.11.2. Market Revenue and Forecast, by Service Type
13.3.11.3. Market Revenue and Forecast, by Clinical Trial Phase
13.3.11.4. Market Revenue and Forecast, by Therapeutic Area
13.3.11.5. Market Revenue and Forecast, by End-User
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type
13.4.2. Market Revenue and Forecast, by Service Type
13.4.3. Market Revenue and Forecast, by Clinical Trial Phase
13.4.4. Market Revenue and Forecast, by Therapeutic Area
13.4.5. Market Revenue and Forecast, by End-User
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type
13.4.6.2. Market Revenue and Forecast, by Service Type
13.4.6.3. Market Revenue and Forecast, by Clinical Trial Phase
13.4.6.4. Market Revenue and Forecast, by Therapeutic Area
13.4.7. Market Revenue and Forecast, by End-User
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type
13.4.8.2. Market Revenue and Forecast, by Service Type
13.4.8.3. Market Revenue and Forecast, by Clinical Trial Phase
13.4.8.4. Market Revenue and Forecast, by Therapeutic Area
13.4.9. Market Revenue and Forecast, by End-User
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type
13.4.10.2. Market Revenue and Forecast, by Service Type
13.4.10.3. Market Revenue and Forecast, by Clinical Trial Phase
13.4.10.4. Market Revenue and Forecast, by Therapeutic Area
13.4.10.5. Market Revenue and Forecast, by End-User
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type
13.4.11.2. Market Revenue and Forecast, by Service Type
13.4.11.3. Market Revenue and Forecast, by Clinical Trial Phase
13.4.11.4. Market Revenue and Forecast, by Therapeutic Area
13.4.11.5. Market Revenue and Forecast, by End-User
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type
13.5.2. Market Revenue and Forecast, by Service Type
13.5.3. Market Revenue and Forecast, by Clinical Trial Phase
13.5.4. Market Revenue and Forecast, by Therapeutic Area
13.5.5. Market Revenue and Forecast, by End-User
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type
13.5.6.2. Market Revenue and Forecast, by Service Type
13.5.6.3. Market Revenue and Forecast, by Clinical Trial Phase
13.5.6.4. Market Revenue and Forecast, by Therapeutic Area
13.5.7. Market Revenue and Forecast, by End-User
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type
13.5.8.2. Market Revenue and Forecast, by Service Type
13.5.8.3. Market Revenue and Forecast, by Clinical Trial Phase
13.5.8.4. Market Revenue and Forecast, by Therapeutic Area
13.5.8.5. Market Revenue and Forecast, by End-User
14.1. Catalent
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Almac Group
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. PCI Pharma Services
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Recipharm
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Syneos Health
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. ICON plc
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Biocair
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Yourway
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Medical Devices
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Laboratory Kits
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description